Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Increases By 8.7%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,000,000 shares, a growth of 8.7% from the August 15th total of 1,840,000 shares. Based on an average daily volume of 188,600 shares, the days-to-cover ratio is currently 10.6 days. Approximately 17.3% of the shares of the company are short sold.

Institutional Trading of Jasper Therapeutics

A number of hedge funds have recently made changes to their positions in JSPR. Ieq Capital LLC bought a new position in Jasper Therapeutics in the 4th quarter worth about $43,000. Rhumbline Advisers bought a new position in Jasper Therapeutics in the 2nd quarter valued at approximately $300,000. Virtu Financial LLC purchased a new stake in Jasper Therapeutics during the 1st quarter valued at $306,000. American Century Companies Inc. increased its holdings in shares of Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics in the first quarter worth $599,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Trading Up 2.0 %

Shares of JSPR stock traded up $0.46 during trading hours on Wednesday, reaching $23.43. The company’s stock had a trading volume of 32,111 shares, compared to its average volume of 138,980. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The stock has a market capitalization of $352.95 million, a P/E ratio of -4.08 and a beta of 2.22. The firm’s fifty day simple moving average is $19.52 and its 200 day simple moving average is $22.72.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.12. As a group, equities research analysts forecast that Jasper Therapeutics will post -4.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on JSPR shares. JMP Securities assumed coverage on shares of Jasper Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $70.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Evercore ISI restated an “outperform” rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. Finally, BTIG Research started coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a “buy” rating and a $90.00 price target on the stock. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $73.00.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.